Page 13 - இந்தியா தேசிய நிறுவனம் ஆஃப் நோயெதிர்ப்பு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from இந்தியா தேசிய நிறுவனம் ஆஃப் நோயெதிர்ப்பு. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In இந்தியா தேசிய நிறுவனம் ஆஃப் நோயெதிர்ப்பு Today - Breaking & Trending Today

India's quick nod to homegrown COVID-19 vaccine seeds doubt

As the director of a large hospital in the Indian state that has seen the country's most coronavirus cases, Dr. S.P. Kalantri had been waiting for the day a vaccine would be approved and bring protection not only to his community but also himself. Many scientists have said that approving a vaccine without evidence from late trials is risky and a lack of transparency in the approval process could increase vaccine hesitancy in the world’s second-most populated country, where more than 10.4 million coronavirus cases have been reported among the nearly 1.4 billion people. The homegrown vaccine was one of two that India authorized for emergency use on Jan. 3. ....

United Kingdom , Narendra Modi , Krishna Ella , Vineeta Bal , Singh Deo , Shahid Jameel , Balram Bhargava , Science Department , India Ashoka University , India National Institute Of Immunology , Indian Council Of Medical Research , Serum Institute Of India , Bharat Biotech , Serum Institute , Minister Narendra Modi , Anant Bhan , National Institute , Indian Council , Medical Research , Associated Press Health , Howard Hughes Medical Institute , Clinical Trials , Vaccine Hesitancy , ஒன்றுபட்டது கிஂக்டம் , நரேந்திர மோடி , கிருஷ்ணா எல்லா ,

Dosing debates, transparency issues roil vaccine rollouts


Science s COVID-19 reporting is supported by the Pulitzer Center and the Heising-Simons Foundation
Last-minute vaccine dosing changes that could gamble away proven COVID-19 protection and undermine public trust. Controversial approvals without any efficacy data. Vaccinemakers at odds with countries hosting their clinical trials. The COVID-19 vaccine landscape keeps changing almost daily, simultaneously raising hopes and triggering confusion and scientific debates. “It s crazy,” says vaccine researcher John Moore of Weill Cornell Medicine. “Every morning, it s just, ‘What s going on?’”
Over the past few weeks, COVID-19 vaccines developed in the United Kingdom, China, and India moved toward widespread rollout, offering new weapons in the face of fast-spreading viral variants that threaten to deepen the crisis (see p. 108). But many came with controversies, and U.K. regulators sparked a debate when they endorsed a sharp departure from the expected dosing schedule ....

United States , Rio De Janeiro , Estado Do Rio , United Kingdom , United Arab Emirates , Moncef Slaoui , John Moore , Paul Offit , Mauro Schechter , Peter Marks , Oxford Adrian Hill , Vineeta Bal , Heising Simons Foundation , University Of Oxford , University Of Rio De Janeiro , Drug Administration , Doctor Association United Kingdom , British Society For Immunology , Central Drugs Standard Control Organisation , Sinopharm China National Biotec Group , Regulatory Agency , College City , Pulitzer Center , India National Institute Of Immunology , Weill Cornell , Natalie Dean ,